236 related articles for article (PubMed ID: 31127821)
1. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
2. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
[TBL] [Abstract][Full Text] [Related]
3. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
[TBL] [Abstract][Full Text] [Related]
4. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
5. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
8. Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.
Uchida T; Nishimoto K; Fukumura Y; Asahina M; Goto H; Kawano Y; Shimizu F; Tsujimura A; Seki T; Mukai K; Kabe Y; Suematsu M; Gomez-Sanchez CE; Yao T; Horie S; Watada H
Endocr Pathol; 2017 Mar; 28(1):27-35. PubMed ID: 27430645
[TBL] [Abstract][Full Text] [Related]
9. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression.
Liakos P; Lenz D; Bernhardt R; Feige JJ; Defaye G
J Endocrinol; 2003 Jan; 176(1):69-82. PubMed ID: 12525251
[TBL] [Abstract][Full Text] [Related]
11. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase.
Engelhardt D; Dörr G; Jaspers C; Knorr D
Klin Wochenschr; 1985 Jul; 63(13):607-12. PubMed ID: 2993735
[TBL] [Abstract][Full Text] [Related]
12. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
13. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
14. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells.
Lamberts SW; Bons EG; Bruining HA; de Jong FH
J Pharmacol Exp Ther; 1987 Jan; 240(1):259-64. PubMed ID: 3027305
[TBL] [Abstract][Full Text] [Related]
16. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
17. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole inhibits human adrenocortical steroidogenesis in vitro.
van der Pas R; Hofland LJ; Hofland J; Taylor AE; Arlt W; Steenbergen J; van Koetsveld PM; de Herder WW; de Jong FH; Feelders RA
J Endocrinol; 2012 Dec; 215(3):403-12. PubMed ID: 23038793
[TBL] [Abstract][Full Text] [Related]
19. Physiological and drug-induced changes in blood levels of adrenal steroids and their precursors in cynomolgus monkeys: An application of steroid profiling by LC-MS/MS for evaluation of the adrenal toxicity.
Tochitani T; Yamashita A; Matsumoto I; Kouchi M; Fujii Y; Yamada T; Miyawaki I
J Toxicol Sci; 2019; 44(9):575-584. PubMed ID: 31474739
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
